Treatment with 5-AminoLEvuliNic acid before cardiac surgery (TALEN)

  • Research type

    Research Study

  • Full title

    Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study

  • IRAS ID

    280513

  • Contact name

    Arash Yavari

  • Contact email

    ayavari@well.ox.ac.uk

  • Sponsor organisation

    University of Oxford / Clinical Trials and Research Governance

  • Eudract number

    2020-001135-27

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    This study is looking to find the best dose of a drug called 5-ALA given with iron given before coronary artery bypass graft (CABG) surgery to see whether it can protect the heart and vital organs from the stress of cardiac surgery.

    CABG surgery is used to improve the flow of blood to the heart muscle. During the operation, blood flow to the heart is interrupted for a period of time while on a heart-lung machine. This allows the surgeon to operate on the heart but carries a risk of damage to the heart and other organs, such as the brain and kidneys. This study looks at a new way to protect the heart and other organs from this potential damage by preparing it for CABG surgery through harnessing a natural defence mechanism.

    5-ALA is the short name for 5-aminolevulinic acid. 5-ALA is an amino acid (a building block of proteins) that is naturally present in food and drink such as red wine, Asian ginseng, green tea and vinegar. 5-ALA is also made naturally by the body and used to produce haemoglobin needed to make red blood cells. 5-ALA switches on a protein found in the body called HO-1 (haem oxygenase-1). HO-1 is a key cellular defence protein that is rapidly activated in response to stress and injury to protect cells. By giving ALA for a few days before surgery, this study aims to prime the HO-1 system to boost its ability to protect the heart and other organs during the operation. Specifically, the study will test different doses of 5-ALA to find the most effective and safe dose to activate HO-1.

  • REC name

    South Central - Oxford A Research Ethics Committee

  • REC reference

    20/SC/0272

  • Date of REC Opinion

    11 Sep 2020

  • REC opinion

    Further Information Favourable Opinion